Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilities

Medical Mycology

Volumn 45, Issue 2, 2007, Pages 173-181

  Kantarcioǧlu, A Serda ^a   Boekhout, Teun ^b,c   De Hoog, G Sybren ^b,d   Theelen, Bart ^b   Yücel, Ayhan ^a   Ekmekci, Tuba ^e   Fries, Bettina ^f   Ikeda, Reiko ^g   Koslu, Adem ^e   Altas, Kemal ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Research Hospital   (Turkey)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antifungals; Cryptococcal antigens; Cryptococcus diffluens; Phenotypical switching; Primary subcutaneous cryptococcosis

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TERBINAFINE;

ADOLESCENT; ARTICLE; CASE REPORT; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS DIFFLUENS; CRYPTOCOCCUS NEOFORMANS; DERMATOMYCOSIS; DRUG SENSITIVITY; FUNGAL VIRULENCE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PYODERMA; SKIN ABSCESS; SKIN BIOPSY; SKIN EXAMINATION; SPOROTRICHOSIS; SUBCUTANEOUS NODULE;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BASE SEQUENCE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DIAGNOSIS, DIFFERENTIAL; DNA, FUNGAL; DNA, RIBOSOMAL; DNA, RIBOSOMAL SPACER; DRUG RESISTANCE, FUNGAL; FLUCYTOSINE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; RNA, RIBOSOMAL, 28S; SEQUENCE ANALYSIS, DNA; SPOROTRICHOSIS;

CRYPTOCOCCUS DIFFLUENS; FUNGI;

EID: 33847754993     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780601045166     Document Type: Article

References (44)

1. Boekhout, T. and Gueho, E. (2003) Basidiomycetous yeasts. Pathogenic Fungi in Humans and Animals, pp. 535-564. Marcel Dekker, New York
2. De Hoog, GS, Guarro, J. and Gené, JL (2000) Atlas of Clinical Fungi, pp. 132-133. Centraalbureau voor Schimmelcultures, Universitat Rovira i Virgili, Utrecht/Reus
3. Ikeda, R., Sugita, T. and Shinoda, T. (2000) Serological relationship of Cryptococcus spp.: Distribution of antigenic fators in Cryptococcus and intrapsecies diversity. J Clin Microbiol, 38, pp. 4021-4025.
4. Bauters, TGM, Swinne, D. and Boekhout, T. (2002) Repeated isolation of Cryptococcus laurentii in the oropharynx despite treatment with fluconazole. Mycopathologia, 153, pp. 133-135.
5. Averbuch, D., Boekhout, T. and Falk, R. (2002) Fungemia in a cancer patient caused by fluconazole resistant Cryptococcus laurentii. Med Mycol, 40, pp. 479-484.
6. Kordossis, T., Avlami, A. and Velegraki, A. (1998) First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol, 36, pp. 335-339.
7. Sugita, T., Takashima, M. and Ikeda, R. (2000) Intraspecies diversity of Cryptococcus laurentii as revealed by sequences of internal transcribed spacer regions and 28S rRNA gene and taxonomic position of C. laurentii clinical isolates. J Clin Microbiol, 38, pp. 1468-1471.
8. Takashima, M., Sugita, T. and Shinoda, T. (2003) Three new combinations from the Cryptococcus laurentii complex: Cryptococcus aureus, Cryptococcus carnescens and Cryptococcus peneaus. Int J Syst Evol Microbiol, 53, pp. 1187-1194.
9. Rimek, D. (2004) First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol, 42, pp. 481-483.
10. Tintelnot, K. and Lostert, H. (2005) Isolation of Cryptococcus adeliensis from clinical samples and the environment in Germany. J Clin Microbiol, 43, p. 1007.
11. Dromer, F., Moulignier, A. and Dupont, B. (1995) Myeloradiculitis due to Cryptococcus curvatus in AIDS. AIDS, 9, pp. 395-396.
12. (1899)
13. Sugita, T., Takashima, M. and Ikeda, R. (2001) Intraspecies diversity of Cryptococcus albidus isolated from humans as revealed by sequences of the internal transcribed spacer regions. Microbiol Immunol, 45, pp. 291-297.
14. Adams, ED and Cooper, BH. (1974) Evaluation of a modified Wickerham medium for identifying medically important yeasts. Am J Med Technol, 40, pp. 377-388.
15. (1984) The Yeasts: A Taxonomic Study, Elsevier Science Publishers BV
16. Chung, KJ Kwon and Bennett, JE (1992) Medical Mycology, p. 819.
17. Pal, M., Onda, C. and Hasegawa, A. (1990) Isolation of saprophytic Cryptococcus neoformans. Jpn J Vet Sci, 52, pp. 1171-1174.
18. Pal, M. (1899) Pulmonary mycosis in a pigeon handler due to Cryptococcus neoformans var. neoformans. 2nd International Conference on Cryptococcus and cryptococcosis Milan, (Italy)
19. Bolano, A., Stinchi, S. and Preziosi, R. (2001) Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res, 1, pp. 221-224.
20. Gupta, AK, Boekhout, T. and Theelen, B. (2004) Identification and typing of Malassezia species by amplified fragment length polymorphism (AFLP) and sequence analysis of the internal transcribed spacer (ITS) and large subunit (LSU) regions of ribosomal DNA. J Clin Microbiol, 42, pp. 4253-4260.
21. Ikeda, R., Shinoda, T. and Fukazawa, Y. (1982) Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol, 16, pp. 22-29.
22. (2002) National Committee for Clinical Laboratory Standards Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. National Committee for Laboratory Standards, National Committee for Laboratory Standards, Wayne, PA
23. Viviani, MA, Esposto, MC and Cogliati, M. (2003) Flucytosine and cryptococcosis: Which in vitro test is the best predictor of outcome?. J Chemother, 15, pp. 124-128.
24. Rodriguez-Tudela, JL, Martin-Diez, F. and Cuenca-Estrella, M. (2000) Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: A comparison of the NCCLS standard M27-A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother, 44, pp. 400-404.
25. Lozano-Chiu, M., Paetznick, VL and Ghannoum, MA (1998) Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: Performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol, 36, pp. 2817-2822.
26. Casadevall, A., Mukherjee, J. and Devi, SJ (1992) Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis, 165, pp. 1086-1093.
27. Ellis, HT and William, WJ. (2001) Sporotrichoid lymphocutaneous infections: Aetiology, diagnosis and therapy. Am Fam Physic, 63, pp. 326-332.
28. Ryncarz, RE, Heasley, EC and Babinchak, TJ. (1999) The clinical spectrum of nodulary lymphangitis. Hosp Physic, 9, pp. 63-66.
29. Kostman, JR and DiNubile, MJ. (1993) Nodulary lymphangitis: A distinctive but often unrecognized syndrome. Ann Intern Med, 118, pp. 883-888.
30. Wilson, JW. (1963) Cutaneous (chancriform) syndrome in deep mycoses. Arch Dermatol, 87, pp. 121-125.
31. Rippon, JW. (1988) Medical Mycology, p. 666. WB Saunders Company, Philadelphia
32. Ng, WF and Loo, KT. (1994) Cutaneous cryptococcosis-primary versus secondary disease. Report of two cases with review of literature. Am J Dermatopathol, 16, p. 227.
33. Neuville, S., Dromer, F. and Morin, O. (2003) Primary cutaneous cryptococcosis: A distinct clinical entity. Clin Infect Dis, 36, pp. 337-347.
34. Narayan, S., Batta, K. and Colloby, P. (2000) Cutaneous cryptococcosis infection due to C. albidus associated with Sezary syndrome. Br J Dermatol, 143, pp. 632-634.
35. Christianson, JC, Engber, W. and Andes, D. (2003) Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol, 41, pp. 177-188.
36. Ellis, DH and Pfeiffer, TJ. (1990) Ecology, life cycle and infectious propagules of Cryptococcus neoformans. Lancet, 336, pp. 923-925.
37. Lazera, MS, Pires, FDA and Camillo-Coura, L. (1996) Natural habitat of Cryptococcus neoformans var.gattii in decaying wood forming hollows in living trees. J Vet Med Mycol, 34, pp. 127-131.
38. Lazera, MS, Salmito, MA and Londero, AT (2000) Possible primary ecological niche of Cryptococcus neoformans. Med Mycol, 38, pp. 379-383.
39. Fonseca, A., Scorzetti, G. and Fell, JW. (2000) Diversity in the yeast Cryptococcus albidus and related species revealed by ribosomal DNA sequence analysis. Can J Microbiol, 46, pp. 7-27.
40. Odds, FC, De Backer, T. and Dams, G. (1995) Oxygen as limiting nutrient for growth of Cryptococcus neoformans. J Clin Microbiol, 33, pp. 995-997.
41. Cuenca-Estrella, M., Gomez-Lopez, A. and Mellado, E. (2004) In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother, 48, pp. 3107-3111.
42. Ghannoum, MA and Ibrahim, AS (1992) Susceptibility testing of Cryptococcus neoformans: A microdilution technique. J Clin Microbiol, 30, pp. 2881-2886.
43. Witt, MD, Lewis, RJ and Larsen, RA (1996) Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis, 22, pp. 322-328.
44. Krajden, S., Summerbell, RC and Kane, J. (1991) Normally saprobic cryptococci isolated from Cryptococcus neoformans infections. J Clin Microbiol, 29, pp. 1883-1887.